Zura Bio Ltd
ZURADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
ZURA Earnings Report
EPS Est: $-0.20 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ZURA's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tibulizumab Dose A | Phase 2 | Hidradenitis Suppurativa (HS) | - | - |
Tibulizumab | Phase 2 | Systemic Sclerosis (SSc) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Zura Bio Ltd's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Zura Bio Ltd's (ZURA) pipeline across Phase 2. Its lead program is Tibulizumab Dose A (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zura Bio Ltd's next FDA catalyst?→
Zura Bio Ltd's (ZURA) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZURA biotech catalysts?→
Add ZURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zura Bio Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.